LRRK2-lowering therapies have been proposed in clinical trials for other neurogenerative diseases.30 However, the link between LRRK2 levels and regional in vivo brain inflammation in PSP remains to be elucidated. This evidence concerns the gene LRRK2 and supranuclear palsy, progressive, 1.